Evidence map›Paper›PMID 24700870›Full record

ReviewJournal of the American Society of Nephrology : JASN2014

Assessment and management of hypertension in patients on dialysis.

Rajiv Agarwal, Joseph Flynn, Velvie Pogue, Mahboob Rahman, Efrain Reisin, Matthew R Weir

2 registry-linked trialsAbstract readReview
In one paragraph

Review in Journal of the American Society of Nephrology : JASN, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 74 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07753876 enrolling by invitationnot on this mapstarted 2025, after this paper: background citation

Evaluation of Cuffless Blood Pressure Monitoring in Hemodialysis (CURE-HD) Study

TypeobservationalSponsorGangnam Severance HospitalRan2025 to 2026Enrolled240ConditionsEnd-Stage Renal DiseaseArmsCART BP Pro
NCT07762859 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Wearable Ambulatory Versus Office Blood Pressure-Guided Hypertension Management in Hemodialysis Patients: A Multicenter, Single-Blind, Randomized Controlled Trial

TypeinterventionalSponsorGangnam Severance HospitalRan2026 to 2027Enrolled280ConditionsESRD on HDArmsCART BP Pro-guided blood pressure management, Conventional office blood pressure-guided management
3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Guideline
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Safety and Short-Term Effects of Empagliflozin in Patients with Heart Failure and End-Stage Renal Disease.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026
    Trial
  7. Trial
  8. Effect of lisinopril and atenolol on aortic stiffness in patients on hemodialysis.Clinical journal of the American Society of Nephrology : CJASN · 2015
    Trial
  9. Trial
  10. Trial
  11. Observational
  12. Article
  13. Review
  14. Review
  15. Combined blood pressure and pulse rate as a new risk marker for mortality in hemodialysis patients.Hypertension research : official journal of the Japanese Society of Hypertension · 2025
    Article
  16. Article
  17. Observational
  18. Observational
  19. Article
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rajiv AgarwalDivision of Nephrology, Department of Medicine, Indiana University School of Medicine and Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana; ragarwal@iupui.edu.
Joseph FlynnDivision of Nephrology, Seattle Children's Hospital, University of Washington, Seattle, Washington;
Velvie Pogueformerly Division of Nephrology, Harlem Hospital, Columbia University College of Physicians & Surgeons, New York, New York;
Mahboob RahmanDivision of Nephrology and Hypertension, University Hospitals Case Medical Center, Louis Stokes Cleveland Veterans Affairs Medical Center, Case Western Reserve University, Cleveland, Ohio;
Efrain ReisinDivision of Nephrology and Hypertension, Louisiana State University Health Science Center, New Orleans, Louisiana; and.
Matthew R WeirDivision of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.

Funding

Hypertension in Hemodialysis PatientsR01DK062030 · NIDDK · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI AGARWAL, RAJIV · 2003 to 2013
$3.8M
NIDDK NIH HHS 2R01-DK6203010
6 · The paper itself

Abstract

Hypertension is common, difficult to diagnose, and poorly controlled among patients with ESRD. However, controversy surrounds the diagnosis and treatment of hypertension. Here, we describe the diagnosis, epidemiology, and management of hypertension in dialysis patients, and examine the data sparking debate over appropriate methods for diagnosing and treating hypertension. Furthermore, we consider the issues uniquely related to hypertension in pediatric dialysis patients. Future clinical trials designed to clarify the controversial results discussed here should lead to the implementation of diagnostic and therapeutic techniques that improve long-term cardiovascular outcomes in patients with ESRD.

Indexed as

Renal DialysisAdultAge FactorsAntihypertensive AgentsChildHumansHypertensionKidney Failure, ChronicAntihypertensive Agentsdialysishemodialysishypertension

Identifiers

PMID24700870
PMCPMC4116052

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.